<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MAPROTILINE HYDROCHLORIDE</span><br/>(ma-proe'ti-leen)<br/><span class="topboxtradename">Maprotiline HCl<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">psychotherapeutic</span>; <span class="classification">tetracyclic antidepressant</span><br/><b>Prototype: </b>Mirtazapine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 75 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Tetracyclic antidepressant pharmacologically and therapeutically similar to the tricyclic antidepressants. Has significant
         sedative effect and less prominent anticholinergic action; may lower seizure threshold. Precise mechanism is unknown, however,
         it blocks the reuptake of norepinephrine at the neural membranes.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Useful in depression associated with anxiety and sleep disturbances.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder).</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Bulimia, pain, panic attack.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patients 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of seizure activity. Also see precautions under imipramine HCl.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Mild to Moderate Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start at 75 mg/d and gradually increase q2wk up to 150 mg/d in single or divided doses<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 25 mg h.s. and gradually increase to 5075 mg/d<br/><br/><span class="indicationtitle">Severe Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start at 100150 mg/d and gradually increase up to 300 mg/d in single or divided doses if needed<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give as single dose or in divided doses. Initiate therapy with low dosages to reduce risk of seizures.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise specified.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Seizures, exacerbation of psychosis, hallucinations, tremors, excitement, confusion, dizziness, <span class="speceff-common">drowsiness</span>. <span class="typehead">CV:</span>
<span class="speceff-common">Orthostatic hypotension,</span> hypertension, tachycardia. <span class="typehead">Special Senses:</span> Accommodation disturbances, blurred vision, mydriasis. <span class="typehead">GI:</span> Nausea, vomiting, epigastric distress, <span class="speceff-common">constipation, dry mouth</span>. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Urinary retention,</span> frequency. <span class="typehead">Skin:</span> Hypersensitivity reactions (skin rash, urticaria, photosensitivity). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease some response to <span class="classification">antihypertensives</span>; <span class="classification">cns depressants</span>, <b>alcohol,</b>
<span class="classification">hypnotics</span>, <span class="classification">barbiturates</span>, <span class="classification">sedatives</span> potentiate CNS depression; may increase hypoprothrombinemic effect of <span class="classification">oral anticoagulants</span>; transient delirium with <b>ethchlorvynol;</b> with <b>levodopa,</b>
<span class="classification">sympathomimetics</span> (e.g., <b>epinephrine</b>, <b>norepinephrine</b>) there is possibility of sympathetic hyperactivity with hypertension and <b>hyperpyrexia;</b> with <span class="classification">mao inhibitors</span> or <b>linezolid</b> there is possibility of severe reactions, toxic psychosis, cardiovascular instability; <b>methylphenidate</b> increases plasma TCA levels; <span class="classification">thyroid drugs</span> increase possibility of arrhythmias; <b>cimetidine</b> may increase plasma TCA levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from GI tract. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> Distributed chiefly to brain, lungs, liver, and kidneys. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 70% excreted in urine, 30% in feces. <span class="typehead">Half-Life:</span> 51 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness; 23 wk are usually necessary for full effect.</li>
<li>Assess level of sedative effect. If recovering patient becomes too lethargic to care for personal hygiene or to maintain food
            intake and interactions with others, report to physician.
         </li>
<li>Monitor bowel elimination pattern and I&amp;O ratio. Severe constipation and urinary retention are potential problems, especially
            in the older adult. Advise increased fluid intake (at least 1500 mL/d).
         </li>
<li>Observe seizure precautions; risk of seizures appears to be high in heavy drinkers.</li>
<li>Bear in mind that if patient uses excessive amounts of alcohol, potentiated effects of maprotiline may increase the danger
            of overdosage or suicide attempt.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report symptoms of stomatitis and dry mouth when taking high doses. Sore or dry mouth can lead to lack of compliance.</li>
<li>Use caution with tasks that require alertness and skill; ability may be impaired during early therapy.</li>
<li>Do not change dose or dose schedule without consulting physician.</li>
<li>Do not use OTC drugs unless approved by physician.</li>
<li>Avoid alcohol; the effects of maprotiline are potentiated when both are used together and for 2 wk after maprotiline is discontinued.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>